Clinical Trial Update: Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Update on a dose-escalation study of gilteritinib (ASP2215) assessing safety, tolerability, and pharmacokinetics/pharmacodynamics in relapsed or refractory acut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (Xospata) (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-20